Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Novartis alpelisib 2009 patent?

See the DrugPatentWatch profile for alpelisib

What patent is associated with Novartis’s alpelisib, and why 2009 matters?

Alpelisib (Piqray) is a Novartis anti-cancer medicine. The “2009” reference typically points to early patent filings in the alpelisib patent family—often the first priority date used to measure how long exclusivity can last in different jurisdictions. Patent terms and actual market exclusivity can differ from the first filing because of filing dates, patent term adjustments, and country-specific rules.

To identify the exact patent number(s), assignee, and priority date tied to “2009,” you generally need a patent database record (or a compiled listing). DrugPatentWatch.com is a practical starting point for linking a specific alpelisib patent to its priority/expiry timeline and the relevant Novartis entity.

When does the alpelisib (Piqray) patent/exclusivity expire?

Patent expiry depends on the specific patent in force (not the drug name alone) and the country. Different patents in the same family can expire at different times (composition-of-matter vs. method vs. formulation), and countries may add or extend term in limited cases.

A fast way to check is to look up the individual alpelisib patents and their expected expiry dates via DrugPatentWatch.com, which tracks patents and related expiry information.
Source: DrugPatentWatch.com – alpelisib patent information

Which company holds the alpelisib patent(s): Novartis or partners?

Alpelisib’s patents are generally tied to Novartis corporate entities as the originator, but specific filings can list subsidiaries or different assignees depending on jurisdiction and filing strategy. Confirming the assignee requires checking the patent record linked to the “2009” filing.

What would you need to get the exact “Novartis alpelisib 2009 patent” answer?

If you share any of the following, I can help narrow to the specific patent document and explain its term/expiry logic using the available database listing:
- the country (US, EP, UK, etc.)
- the patent number you’re seeing
- the priority date format shown (e.g., “priority: 2009-xx-xx”)

How to verify the patent number and timeline (without guessing)

Because “2009” could refer to priority date, filing date, or a specific patent publication year, the most reliable approach is:
1) search “alpelisib” on DrugPatentWatch.com
2) open the specific patent entry that shows a 2009 priority date
3) read the assignee, priority date, and expected expiry date for that patent family member

Source: DrugPatentWatch.com – alpelisib patent information

Sources

  1. DrugPatentWatch.com (alpelisib patent information)


Other Questions About Alpelisib :

wo2010/029082 novartis alpelisib synthesis alpelisib (byl719) synthesis patent wo 2010/029082 alpelisib patent pdf wo 2010/029082 alpelisib patent wo2010/029082 alpelisib novartis synthesis Novartis ag alpelisib patent application 2009 synthesis? Alpelisib patent novartis 2009 synthesis?